Targeted alpha therapy (TAT) with 225Ac has shown promising results even in this challenging group of recurrent prostate cancer patients, pre-treated with [177Lu]Lu-PSMA RLT [5, 6], but commonly induces xerostomia [6]. This evidence concerns the gene FOLH1 and prostate cancer.